We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

170 hedge funds and large institutions have $929M invested in CRISPR Therapeutics in 2019 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

47% more capital invested

Capital invested by funds: $631M → $929M (+$298M)

16% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 38

10% more funds holding

Funds holding: 155 → 170 (+15)

7.11% more ownership

Funds ownership: 42.63% → 49.75% (+7.1%)

35% less call options, than puts

Call options by funds: $14.1M | Put options by funds: $21.6M

Holders
170
Holders Change
+15
Holders Change %
+9.68%
% of All Funds
3.68%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.13%
New
39
Increased
44
Reduced
38
Closed
23
Calls
$14.1M
Puts
$21.6M
Net Calls
-$7.58M
Net Calls Change
-$1.47M

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$57.7M
2
BB
BB Biotech
Switzerland
+$28M
3
CAM
Cormorant Asset Management
Massachusetts
+$27.7M
4
AIM
ARK Investment Management
Florida
+$24.1M
5
VVM
Versant Venture Management
California
+$22.1M

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$18.2M
2
Two Sigma Investments
Two Sigma Investments
New York
-$15M
3
NLVP
New Leaf Venture Partners
New York
-$12.7M
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$8.08M
5
AC
Armistice Capital
New York
-$3.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
Tekla Capital Management
Massachusetts
$6.37M – – –
AG
27
Artal Group
Luxembourg
$5.18M – – –
Capital International Investors
28
Capital International Investors
California
$4.93M – – –
AA
29
ALPS Advisors
Colorado
$4.47M +$219K +6,326 +5%
Bank of Montreal
30
Bank of Montreal
Ontario, Canada
$3.43M +$58.4K +1,690 +2%
SC
31
Sculptor Capital
New York
$2.94M +$2.85M +82,300 New
AI
32
Atom Investors
Texas
$2.86M +$2.77M +80,051 New
AC
33
Armistice Capital
New York
$2.86M -$3.18M -92,000 -53%
Allianz Asset Management
34
Allianz Asset Management
Germany
$2.84M +$593K +17,164 +28%
Two Sigma Investments
35
Two Sigma Investments
New York
$2.73M -$15M -433,260 -85%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$2.52M -$71.1K -2,057 -3%
Royal Bank of Canada
37
Royal Bank of Canada
Ontario, Canada
$2.46M +$310K +8,973 +15%
Vanguard Group
38
Vanguard Group
Pennsylvania
$2.3M +$148K +4,283 +7%
SAMH
39
Shanda Asset Management Holdings
British Virgin Islands
$2.08M – – –
UBS Group
40
UBS Group
Switzerland
$2.02M +$187K +5,400 +11%
CAI
41
Capital Advisors Inc
Oklahoma
$1.88M -$2.26M -65,340 -55%
RJA
42
Raymond James & Associates
Florida
$1.84M +$105K +3,040 +6%
Man Group
43
Man Group
United Kingdom
$1.82M +$1.76M +50,959 New
Korea Investment Corp
44
Korea Investment Corp
South Korea
$1.71M – – –
IIM
45
Ipswich Investment Management
Massachusetts
$1.58M -$26.3K -760 -2%
EP
46
Eversept Partners
New York
$1.51M +$1.47M +42,400 New
Goldman Sachs
47
Goldman Sachs
New York
$1.48M -$353K -10,214 -20%
Geode Capital Management
48
Geode Capital Management
Massachusetts
$1.38M +$125K +3,615 +10%
Swiss National Bank
49
Swiss National Bank
Switzerland
$1.35M +$138K +4,000 +12%
JG
50
Jefferies Group
New York
$1.34M +$1.3M +37,500 New
1
2
3 4 5

CRSP Hedge Fund Activity: Q1 2019 in Review

170 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2019, worth a combined $929M — up 47% from $631M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CRSP positions and 23 closed out — a net gain of 16 holders — while 44 added to existing stakes and 38 trimmed.

The largest buyer was EcoR1 Capital, adding an estimated $57.7M. The largest seller was Farallon Capital Management, cutting an estimated $18.2M.

  • 170 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2019, up from 155 in Q4 2018.
  • Funds reported $929M of CRISPR Therapeutics stock for Q1 2019, up 47% quarter-over-quarter.
  • 39 funds opened new CRISPR Therapeutics positions in Q1 2019 and 23 closed out, a net change of +16 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2019 was EcoR1 Capital, an estimated $57.7M added.
  • The largest CRISPR Therapeutics seller in Q1 2019 was Farallon Capital Management, an estimated $18.2M sold.

Based on aggregated 13F filings for Q1 2019.